Tocofersolan

Summary

Tocofersolan (CHEMBL2108106) is an approved small molecule (ATC A11HA08); indicated across 5 conditions including cholestasis and hypobetalipoproteinemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A11HA08
• Indications: 5 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108106
Name	Tocofersolan
Type	Small molecule
Max phase	4
ATC	A11HA08

Also known as: Liqui-e, Tocofersolan, Tocophersolan, TPG-S, TPGS, Vedrop, Vitamin e polyethylene glycol succinate, TOCOFERSOLAN, tocofersolan

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	5.4	AC50	4000	nM	CHEMBL_ACT_25174673

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cholestasis	4	MONDO:0001751	MONDO:0001751
hypobetalipoproteinemia	3	MONDO:0017774	MONDO:0017774
short bowel syndrome	2	MONDO:0015183	MONDO:0015183
malaria	1	MONDO:0005136	EFO:0001068

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01457690	PHASE3	COMPLETED	Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention
NCT03582384	PHASE2	WITHDRAWN	Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children
NCT01853475	PHASE1	COMPLETED	Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State
NCT01958619	PHASE1	COMPLETED	Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers
NCT02387580	PHASE1	COMPLETED	Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).